Дисертация за присъждане на научна и обр. ст. доктор на маг. фарм. М. Камушева: Фармако икономика на лечението на редки заболявания, ФФ, МУ-София, 2016.
Дисертация за присъждане на научна и обр. ст. доктор на маг. фарм. Н. Герасимов: Медицински изделия във фармацевтичната номенклатура – законодателни и социални аспекти при осигуряването им в България. ФФ, МУ-София, 2016
Методологични указания за представяните документи за оценка на ефикасността, терапевтичната ефективност, безопасността и фармакоикономическите показатели на лекарствени продукти при кандидатстване за поддържане на реимбурсен статус в Позитивния лекарствен списък. NSCRLP, 2015g. http://ncpr.bg/bg/
Наредба № 9/1.12.2015 г. за условията и реда за извършване на оцента на здр. технологии, https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-9-S1-O28
НЦОЗА, Оценка на здр. технологии, http://ncphp.government.bg/ index.php?option=
com_content&view=category&layout=blog&id=358&Itemid=638〈=bg
Петрова Г., Особеност и на ФИ оценки на лекарства за редки заболявания, http://www.parliament.bg/pub/cW/20121102035105rarediseases.pdf
Berman J. Rare diseases and Orphan Drugs. Keys to understanding and treating the Common Diseases, Elsevier, 2014
Commission of the European communities, Proposal for a European Parliament and Council regulation on orphan medicinal products, 1998 http://eur-lex.europa.eu/LexUriServ/
LexUriServ.do?uri=COM:1998:0450:FIN:en:PDF
COUNCIL RECOMMENDATION of 8 June 2009 on an action in the field of rare diseases, Official Journal of the EU, 2009/C151/02, http://eurlex.europa. eu/LexUri-Serv/LexUriServ.do?uri=OJ:C:2009:151:0007:0010:EN:PDF
Discussion paper, EUCOMED, RARE DISEASES AND MEDICAL DEVICES IN THE EU http://archive.eucomed.org/uploads/Modules/Publications/Rare%20diseases%20and%20medical%20technology.pdf
European commission, concept of ‘similar medicinal product’ in the context of the orphan legislation: adaptation to technical progress replies to the public consultation
https://ec.europa.eu/health/sites/health/files/files/orphanmp/2016_07_pc_orphan/
_07_pc_orphan_summary.pdf
Field MJ, Boat T. Rare diseases and orphan products: accelerating research and development.
Institute of Medicine (US) Committee on Accelerating Rare Disease Research and Orphan Product Development, 2010.
Janoudi G1, Amegatse W2, McIntosh B2, Sehgal C2, Richter T2. Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations
from the CADTH common drug review. Orphanet J Rare Dis. 2016
Dec 1;11(1):164.
Lists of medicinal products for rare diseases in Europe, Orphanet report, April 2017, http://www.orpha.net/orphacom/cahiers/docs/GB/list_of_orphan_drugs_in_europe.pdf
M. Kamusheva, A. Stoimenova, M. Doneva, A. Zlatareva, G. Petrova, A CROSS-COUNTRY COMPARISON OF REIMBURSED ORPHAN MEDICINES IN BULGARIA, GREECE AND ROMANIA Biotechnol. & Biotechnol. Eq. 27/2013/5; 4186-4192.
Michael F Drummond, Challenges in the economic evaluation of orphan drugs, Eurohealth, v.14, 16-17.
Nicod E, Kanavos P. SCIENTIFIC AND SOCIAL VALUE JUDGMENTS FOR ORPHAN DRUGS IN HEALTH TECHNOLOGY ASSESSMENT. Int J Technol Assess Health Care. 2016 Jan;32(4):218-232
Ollendorf DA et al. Assessing the effectiveness and value of drugs for rare conditions, Institute for clinical and economic review, 2017, https://icer-review.org/wp-content/uploads/
/02/ICER_Assessing-the-Value-of-Drugs-for-Rare-Conditions_051017.pdf
Orphan Drugs in Development for Rare Diseases. 2011 Report. America’s Biopharmaceutical Research Companies.
Rashmi R Shah. Regulatory framework for the treatment of orphan diseases, Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford Pharma Genesis; 2006
(11). https://www.ncbi.nlm.nih.gov/books/NBK11567/
Rawson NS, Health technology assessment of new drugs for rare disorders in Canada: impact of disease prevalence and cost. Orphanet J Rare Dis. 2017 Mar 23;12(1):59.
Regulation (EC) no 141/2000 of the European parliament and of the Council of 16 December 1999 on orphan medicinal products, Journal of the EC, 2000. http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri= OJ:L:2000:018:0001:0005:en:PDF
Report on Rare Disease Research its Determinants in Europe and the weay forwards. Ayme S, Hivert V, eds. INSERM, May 2011.
T. Zelei, M. Molnár, M. Szegedi, Z. Kaló. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern Europe. Orphanet J Rare Dis, 2016, 11:72
William RH Evans, Rare diseases in general practice: recognising the zebras among the horses British Journal of General Practice, Nov. 2016
Zurynski, Y., Frith, K., Leonard, H. et. al., Rare childhood diseases: how should we respond?, Archives of Disease in Childhood 2008; 93: 1071-1074, www.apsu.org.au/
assets/workshops/rare-diseases/ADC-rare-diseases-how-should-we-respond.pdf
ЕMA, How early access to medicines has helped patients from 2006 to 2016. www.ema.europa.eu/docs/en_GB/document_library/Other/2017/01/WC500219993.pdf
ЕMA, Conditional marketing authorization Report on 10 years of experience at the EMA, //www.ema.europa.eu/docs/en_GB/document_library/Report/2017/01/WC500219991.pdf